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Recent studies have established that dysregulation of the human immune system and 
the reactivation of latent herpesviruses persists for the duration of a 6-month orbital 
spaceflight. It appears certain aspects of adaptive immunity are dysregulated during 
flight, yet some aspects of innate immunity are heightened. Interaction between adap-
tive and innate immunity also seems to be altered. Some crews experience persistent 
hypersensitivity reactions during flight. This phenomenon may, in synergy with extended 
duration and galactic radiation exposure, increase specific crew clinical risks during deep 
space exploration missions. The clinical challenge is based upon both the frequency 
of these phenomena in multiple crewmembers during low earth orbit missions and the 
inability to predict which specific individual crewmembers will experience these changes. 
Thus, a general countermeasure approach that offers the broadest possible coverage 
is needed. The vehicles, architecture, and mission profiles to enable such voyages are 
now under development. These include deployment and use of a cis-Lunar station (mid 
2020s) with possible Moon surface operations, to be followed by multiple Mars flyby 
missions, and eventual human Mars surface exploration. Current ISS studies will continue 
to characterize physiological dysregulation associated with prolonged orbital spaceflight. 
However, sufficient information exists to begin consideration of both the need for, and 
nature of, specific immune countermeasures to ensure astronaut health. This article 
will review relevant in-place operational countermeasures onboard ISS and discuss 
a myriad of potential immune countermeasures for exploration missions. Discussion 
points include nutritional supplementation and functional foods, exercise and immunity, 
pharmacological options, the relationship between bone and immune countermeasures, 
and vaccination to mitigate herpes (and possibly other) virus risks. As the immune 
FiguRe 1 | Graphic which illustrates the translational aspects of the immune system. The cells of the immune system, located in virtually everywhere  
throughout the body, exchange reciprocal information with, and influence/are influenced by, most of the other physiological systems in the human body.  
Therefore, countermeasures for immune may influence other body systems, and conversely any biomedical countermeasures implemented (e.g., for bone)  
during flight may similarly have bystander effects on immunity. (Cellular graphic sourced from “The Biology Project,” University of Arizona.)
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system has sentinel connectivity within every other physiological system, translational 
effects must be considered for all potential immune countermeasures. Finally, we shall 
discuss immune countermeasures in the context of their individualized implementation 
or precision medicine, based on crewmember specific immunological biases.
Keywords: spaceflight, gravity, immunity, viral reactivation, countermeasures
BACKgROuND
The immune system is remarkably complicated, consisting of a 
myriad of distinct cell populations, each with unique function. The 
cells of innate immunity react quickly in a non-antigen-specific 
fashion, whereas cells of adaptive immunity mount a delayed, anti-
gen specific, response that results in long-term memory. The latter 
includes the distinct humoral and cell-mediated populations, and 
contains an ever-growing number of distinct cytokine-mediated 
“biases” of inflammation, including T helper 1 (Th1), T helper 2 
(Th2) and T helper 17 (Th17). Immunity is markedly translational, 
operating throughout the body and exchanging information and 
interfacing with most other body systems, including the nervous 
system (1) and bone (osteo-immunology) (2), and is profoundly 
influenced by factors such as stress, nutrition, and exercise (3) 
(Figure 1). While reductions in immune cell function may result 
in increased susceptibility to infectious disease, syndromes of 
overactive immunity also exist, including allergy, asthma, eczema, 
and autoimmunity. Therefore, the immune system is a unique 
entity that is extremely sensitive and responsive to perturbations 
throughout the body. In order to maintain optimal health of its 
host, the immune system achieves a proper “balance” among its 
various cell subpopulations, however, an extreme environment 
such as space poses a formidable threat to this equilibrium.
THe SPACe eXPOSOMe
Orbital space flight can have negative health effects (4): dys-
regulation of bone homeostasis, muscle loss via hypokinesis, 
vision impairment in some subjects. The immune system is 
FiguRe 2 | NASA Astronaut Peggy Whitson collects a blood sample in the 
European Space Agency “Columbus” module onboard the International 
Space Station. The blood sample was for the study of the immune system of 
astronauts. The blood samples were transported, ambient temperature to 
preserve cell viability, to Earth for terrestrial analysis. The individual depicted 
has provided written consent for the publication of this image. To maintain 
viability, samples were collected during spaceflight in ACD anticoagulated 
tubes. The average delay from collection onboard ISS, through landing, to 
terrestrial analysis in Houston, Texas was ~37 h.
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highly sensitive to different types of stressors—psychological, 
physical, and local environmental (e.g., oxidative and radiation 
exposure). In healthy individuals, the flexibility and resilience of 
the immune system allows rapid recovery with little or no adverse 
effects. Yet, with high intensity and/or duration of extremes in 
environment, disrupted circadian rhythms, altered nutrition, and 
other factors that impact both physiological and psychological 
stress, adverse consequences to the immune system can occur 
(5–7). Environment, often considered as a combination of mul-
tiple “environmental exposures,” is defined as a “non-genetic” 
factor in the broad sense and is one of the three fundamental 
components of precision medicine: lifestyle, environment, and 
genetics (8). Autoimmunity, allergy, chronic infection, and other 
chronic diseases develop predominantly from a combination of 
environmental exposures with restrained genetic background 
influences. It is important to understand the effects of specific 
environmental exposures, especially in space and other extreme 
environments, on well-being, health, and performance (9). Wild 
defines the “exposome” as composed of every exposure to which 
an individual is subjected in his entire life and hence is a function 
of quality, intensity, and duration of the event (10). Especially for 
a space traveler, this exposome can “grow” in all three defined cat-
egories. In the first category, the exposome comprises processes 
internal to the body (including neurohumoral regulation, meta-
bolic changes, immune changes, and aging processes). Second, 
external exposures include conditions much related to space 
flight such as radiation, infectious agents (e.g., increases in 
pathogen virulence), dietary restrictions, microgravity, overloads 
during launch and landing, constant noise, hypodynamia, and 
the influence of hypo magnetic fields in relation to the deep space 
flights; and third, the exposome includes the wider social and 
psychological influences on the crew.
SPACeFLigHT AND THe iMMuNe 
SYSTeM
Over two decades of research has identified a clear “immune 
problem” associated with spaceflight (11–14). Investigations have 
been conducted using astronaut biological specimens (Figure 2), 
cell culture systems, and animal models, in the context of both 
in-flight and ground models. Spaceflight is a unique exposome 
condition where distinct and extreme stressors, some of which 
cannot accurately be replicated on Earth, influence physiology. 
Astronauts are subjected to increased radiation, microgravity and 
persistent fluids shifts, prolonged isolation and confinement, 
circadian shifts that are difficult to re-entrain, with complicated 
work tasks and schedules. Immune system dysregulation has 
now been demonstrated to occur during flight and persist dur-
ing 6-month orbital spaceflight (13, 15–18). The phenomenon 
typically occurs concurrently with persistent reactivation and 
shedding of latent herpesviruses. As a healthy immune system is 
necessary to suppress latent virus reactivation, it is possible that 
the reactivation of these latent herpesviruses could be a “bio-
marker” of compromised adaptive immune function, particularly 
cytotoxic T lymphocyte function. The precise nature of immune 
dysregulation during spaceflight is currently under investigation; 
however, studies to date have demonstrated altered distribution of 
peripheral leukocytes, diminished function of specific leukocyte 
subpopulations, and skewed cytokine profiles in many astronauts. 
Mehta et  al. positively correlated plasma cytokine alterations 
with viral shedding in specific crewmembers, and postulated a 
Th2 shift associated with flight (19). Therefore, we may infer a 
causal relationship between immune dysregulation (particularly 
cytotoxic function) and viral reactivation in the space environ-
ment. The review of in-flight clinical events in astronauts suggests 
that despite ultimate isolation from terrestrial pathogens, there is 
an increased incidence of infectious disease as well as increased 
allergic symptoms and persistent skin hypersensitivity reactions 
in some crewmembers during orbital flight (20–22).
The use of terrestrial “analogs” of spaceflight can assist in 
determining the mechanism of the spaceflight phenomena and 
may simulate some discipline-specific variables with high fidelity 
(23). Examples include prolonged bed rest to recapitulate bone 
and muscle loss, closed chamber habitats (in laboratory), or field 
deployment such as Antarctic winterover for the effects of human 
isolation on human neuro-physiology, and modeled micrograv-
ity cell culture for the unique space environment (24). Russia, 
at its IBMP facility and with a wide international cooperation, 
employs several unique analogs such as extended duration Mars 
closed-chamber vehicle simulation (“Mars-500”), and a unique 
“dry” immersion hypokinesis. Currently, this facility is being used 
to perform a terrestrial experiment (“SIRIUS”), which simulates 
a lunar space mission and presence on a lunar station. This work 
will be relevant for the upcoming “Deep Space Gateway” project 
(deployment of a cis-Lunar space station) for physiological 
research and the evaluation of potential countermeasures. The 
advantages of terrestrial analogs over the real space flight are 
larger availability of biomaterials; a larger number of subjects, 
FiguRe 3 | Listing of likely biomedical and/or operational countermeasures for deep space exploration missions with the potential to benefit spaceflight-associated 
dysregulation of the human immune system. Broadly, the countermeasures may be considered general/operational multisystem influencing the entire crew, or 
specific biomedical treatments (generally ingestible). A third category, precision or personalized, describes the possibility to “screen” crewmembers pre-flight to 
determine their unique immunological biases or susceptibilities, against which specific in-flight countermeasures may be tailored for individual crewmembers.
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the presence of qualified medical aid, and typically reduced costs 
compared to spaceflight. However, no analog may replicate all 
of the in-flight variables. Therefore, analog data and/or analog 
validation of countermeasures must be interpreted appropriately 
and followed by (if possible) spaceflight investigations.
Logically, any clinical risks to astronauts that manifest dur-
ing orbital spaceflight may be expected to rise during deep 
space, exploration-class missions (25). This is primarily due 
to extended mission duration, increased radiation exposure 
(both duration and magnitude), hypomagnetic environment, and 
limited clinical care combined without a rapid return option 
for emergency situations. The time of “first” space missions has 
passed (generally focused more on the mission rather than the 
science), and collectively we now focus our attention on preserv-
ing astronauts’ health during upcoming deep space exploration 
missions. Therefore, now is the appropriate time to consider 
countermeasure development and validation to enable deep 
space missions with optimal crew safety. This review will discuss 
already existing immune countermeasures, likely future options 
including nutritional supplements to “boost” selected aspects 
of immunity, as well as possible pharmacological interventions 
(Figure 3). Care will be taken to consider the translational effects 
of potential countermeasures on other physiological systems, as 
well as the possibility of “individualized” countermeasures based 
on a particular crewmember’s unique clinical immunological 
history.
OPeRATiONAL PROCeDuReS iN PLACe 
TO LiMiT iMMuNe RiSK
Although not classical “immune countermeasures” in the sense 
that they stabilize dysregulated immune function, there are a 
number of in-place countermeasures that do mitigate clinical 
risks related to immunity, primarily risk of infectious disease (26).
Likely the first immune countermeasure, the Flight Crew 
Health Stabilization Program (HSP) was implemented during 
the Apollo program to reduce the instances of infectious disease 
among astronaut flight crews in the immediate pre-flight/in-flight 
period (27). Infectious diseases can result from direct person- 
to-person contact or through contact with pathogens in the local 
environment. The HSP defined certain controls to minimize crew 
exposure to pathogens by providing a quarantine situation for the 
crew that reduces contact with potential pathogens by limiting 
the number of individuals who come in immediate contact with 
the crew. The likelihood of these primary contact individuals 
5Crucian et al. Immunology Countermeasures for Spaceflight
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1437
being infectious is further reduced by educating them in ways to 
transfer infections and by avoiding contact with the crew if they 
are or possibly may be ill. After implementation, there was a dras-
tic reduction in incidence of infectious disease among flight crew.
Furthermore, for ISS, there are specific vehicle design controls 
intended to reduce infectious disease risk. These include the use 
of HEPA air filters, in-line water filters, contamination resistant 
surfaces, water biocides, a water pasteurization system, efforts 
to minimize condensation, and to contain trash and human 
waste. Microbiological monitoring before launch is performed, 
including screens of crewmembers, food, potable water, vehicle 
surfaces, vehicle air, and various cargo, and a biosafety review of 
payloads. Monitoring for microbial contamination onboard ISS 
includes surfaces, air, and water.
There are also pre-flight medical screenings of ISS crew-
members (26). There have been switches of prime to backup 
ISS crewmembers (occasionally near to launch), some of which 
may have been due to issues detected during medical screening. 
For ISS crews, current components of the “medical operations” 
screens include CBC/differential, C-reactive protein, murine 
allergen-specific IgE Panel, nasal screen for methicillin resistant 
Staphylococcus aureus, as well as a screen to detect and eradicate 
Helicobacter pylori from crewmembers (serological H. pylori IgG 
and IgA antibody test results; urea breath test results, if indicated).
NuTRiTiON/FuNCTiONAL FOODS
Disruption of nutritional balance and inadequate nutrient supply 
may affect immune function. It is well known that macronutrient 
and/or micronutrient insufficiencies or deficiencies can have 
profound effects on immune function (28). Although crewmem-
bers on board the ISS are not afforded an optimized diet, the 
average caloric intake has improved significantly in recent years 
(29, 30). Hypocaloric nutrition, often observed in earlier space 
missions, is associated with increased inflammation and oxida-
tive stress (31, 32), and protein is the most limiting factor when 
the body is deprived of energy (33). Oxidative stress induces 
damage, which results in immune activation and inflammation 
processes. On deep space missions beyond low earth orbit (LEO), 
ionizing radiation and other factors may increase oxidative stress 
and alter the rate of DNA damage and the effectiveness of DNA 
repair mechanisms, exacerbating inflammation and DNA dam-
age. Increased DNA damage further increases oxidative stress, 
leading to a spiral end result yielding chronic inflammation and 
ultimately failure of immune system function.
Protein intake during flight typically exceeds dietary recom-
mendations, and it is generally assumed that all indispensable 
amino acids are also provided in sufficient amounts (34, 35). 
Altering dietary amino acid composition or concentration of 
certain amino acids in food products may differentially affect 
immune system function. Supplementing whey protein, which 
has a high leucine content, has been shown to enhance natural 
killer (NK) cell function and IL-12 concentration (36) and increase 
plasma glutathione concentrations in HIV-infected patients (37). 
While further study is required, provision of protein- and/or 
amino acid-rich foods and/or supplements might be a means to 
maintain immune system function on exploration missions.
Glutathione is the most abundant endogenous intracellular 
antioxidant and plays a central role in antioxidant defenses. 
Glutathione concentrations decline with aging (38–41). Glutathione 
is synthesized from the amino acids cysteine and glycine; and 
in older adults, increasing dietary intake of these amino acids 
brought reduced glutathione levels back to the concentration in 
young controls (42). In a limited number of mice flown to ISS 
for 3  months, red blood cell glutathione concentrations were 
higher than in ground controls, an effect suggesting an adapta-
tion to increased oxidative stress (43). One could speculate that 
providing food products rich in cysteine and glycine may support 
glutathione synthesis to help mitigate oxidative stresses during 
spaceflight.
Diets rich in fruit and vegetables, which contain micronutri-
ents such as carotenoids, flavonoids, vitamin C, and folate, have 
been shown to improve immune function in elderly subjects 
(44) and/or have reduced inflammatory processes (45). In a 
randomized controlled trial in 80 elderly subjects (65–85 years 
old), when subjects ate five portions of fruit and vegetables per 
day, they had a greater number of NK cells present in their blood 
and more improved Pneumovax II antibody response (a marker 
of improved immune system function) than subjects who ate two 
portions of fruit and vegetables daily (44). The effect of fruit juices 
or fruit and vegetable juices, either fresh or as a freeze-dried juice 
blend powder, on immune function have also been examined. In 
competitive athletes, drinking 456 g of juice (containing 230 mg 
flavonoids) for 10 or 17 days did not affect chronic resting or post-
exercise markers of inflammation, oxidative stress, or immune 
function, or shifts in metabolites (46, 47); whereas a fruit and veg-
etable juice powder concentrate consumed for 77 days increased 
antioxidant capacity and reduced DNA strand breaks (48).
In general, the ISS food system is rather dominated by meat 
and meat products and is low in fruits and vegetables. Although 
strong scientific evidence is lacking on whether increasing fruit 
and vegetable consumption can improve immune function, sev-
eral studies show positive effects in certain groups, for instance 
the elderly people, who suffer from reduced immune function. 
An important first step toward improving immune function on 
exploration missions would be to investigate increasing fruit 
and vegetable intake in terrestrial analog experiments followed 
by orbital spaceflight, and to document the effects of such an 




Whether isolated nutrients provided as supplements have effects 
similar to those of the same nutrients provided in a food matrix 
is still an open question (49). Whole fresh foods and a balanced 
diet provide all essential nutrients and thousands of bioactive 
compounds with synergistic benefits that cannot be replicated by 
a supplement. In addition, several vitamins have upper tolerable 
limits, and any supplementation must be considered in context to 
the nutrients provided within the food system to avoid toxic effects. 
However, supplementation of micronutrients such as vitamins E, 
6Crucian et al. Immunology Countermeasures for Spaceflight
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1437
A, and C, which are cofactors in the immune response, has been 
examined as have naturally occurring polyphenols (discussed 
below) (50, 51).
Vitamin E is a strong antioxidant that can support monocyte- 
or macrophage-mediated responses (52). Vitamin A is not an 
antioxidant, but it provides benefit related to possible boosting 
of immune reactions (53). Vitamin A deficiency impairs mucosal 
barriers and diminishes the function of neutrophils, macrophages, 
and NK cells (53, 54). The considerable immune benefits, which 
would contribute to reducing the risk of contracting various 
pathogen-mediated diseases, warrant a recommendation to ensure 
adequate vitamin A intake and status in all astronauts on explo-
ration missions, and to supplement individuals having poor 
vitamin A status. However, there are no known benefits to the 
immune system of providing excess vitamin A (55, 56). The space 
food system already provides vitamin A at the upper tolerable 
limit, and additional supplementation could have adverse health 
implications (50, 57, 58).
Vitamin C is a regulator of redox and metabolic checkpoints 
controlling activation and survival of immune cells (59). Vitamin 
C is an essential component of every living cell. The concentration 
of vitamin C is very high in leukocytes, but fighting off oxida-
tive damage during infection causes the vitamin to be depleted 
rapidly. Vitamin C deficiency is associated with reduced immune 
function (60), with prolonged deficiency leading to scurvy. The 
immune-enhancing role of vitamin C has been reviewed (61, 62), 
and vitamin C has been shown to stimulate cellular functions of 
both the innate and adaptive immune systems. Vitamin C pro-
motes oxidant-scavenging activity in skin, most likely protecting 
against environmental oxidative stressors (62).
Astronauts need to be adequately supplied with vitamins 
E, A, and C. Whether provision of larger amounts of these as 
nutraceuticals will be beneficial for immune function warrants 
further investigation, on Earth and in space.
The classical function of vitamin D is to regulate calcium 
homeostasis through effects on gastrointestinal absorption of 
calcium, and on bone formation and resorption. However, recent 
publications demonstrate that vitamin D also affects other bio-
logical processes including modulation of the immune system. Its 
effect on immunity seems to be mediated by the (nuclear) vitamin 
D receptor (VDR) expressed by antigen-presenting cells and also 
activated T cells (63). Vitamin D and the VDR are necessary for 
the number of regulatory T cells (Tregs) to be normal.
The discovery that VDR expression is inducible in lymphocytes 
after they are activated suggests a role for 1,25-dihydroxyvitamin 
D3 [1,25(OH)2D3], the active form of vitamin D, in the immune 
system (64). Moreover, active macrophages express the enzyme 
25(OH)D3-1-α-hydroxylase, which converts an inactive form 
of vitamin D to the active form, enabling synthesis and secre-
tion of 1,25(OH)2D3 (65). However, here the enzyme is mainly 
activated by immune signals such as interferon-γ rather than by 
parathyroid hormone, which is the primary mediator of vitamin 
D activation in the kidney (63). Moreover, 1,25(OH)2D3 can also 
increase the ability of peripheral blood mononuclear cells from 
sensitized human donors to resist microbes (e.g., mycobacteria). 
Martineau et al. found that 1,25(OH)2D3 suppressed both bacil-
lus Calmette Guérin-infected cell cultures and Mycobacterium 
tuberculosis likely through “nonclassical” mechanisms including 
the induction of antimicrobial peptides (66, 67).
Evidence exists that a higher vitamin D status was related 
to a lower probability of viral shedding in saliva, in individuals 
wintering over in the Antarctic who had high serum cortisol 
(68). Hence, a low vitamin D status of astronauts during space 
missions, which have inherent stressful elements, might affect 
the astronauts’ immune system function. An evaluation of the 
relationship between vitamin D status (and nutritional status in 
general) and immune system function in astronauts is needed. In 
addition, the lack of data on therapeutic effects of vitamin D sup-
plementation when levels of 25(OH)D3, the substrate of 25(OH)
D3-1-α-hydroxylase, are sufficient (69) warrants further studies.
Polyphenols (e.g., resveratrol, quercetin, catechins, and cur-
cumin), have antioxidant and anti-inflammatory benefits (51). 
These effects are modulated via multiple routes, including nuclear 
factor-kappaB (NF-κB)- and mitogen-activated protein kinase-
dependent pathways, and through prevention of the generation 
of reactive oxygen species by binding iron (70). Polyphenols 
can also activate sirtuin 1 (SIRT1), directly or indirectly, and 
thus help mitigate oxidative stress, inflammation, and autoim-
munity. In addition, polyphenols exhibit an immunoregulatory 
role, evidenced both in vitro and in vivo (71–77). Further work 
is needed, but polyphenols may also aid in the prevention of 
immune dysfunction during long-term space missions. This 
is potentially important given that body iron stores are higher 
during spaceflight, and this has been associated with oxidative 
stress and regional bone loss (28). The exact role of polyphenols in 
SIRT1-mediated or iron-related regulation in immune function is 
as of yet undefined, but polyphenols could play an important role 
as a countermeasure in exploration missions.
Omega-3 fatty acids are long-chain, polyunsaturated fatty 
acids, and there is literature documenting their beneficial effects 
on immune and other systems (78, 79). Omega-3 fatty acids can 
even protect from radiation-induced or other oxidative damage 
(80–83). There are several potential mechanisms, likely related 
to redundant pathways, one specifically is that NF-κB, a nuclear 
transcription factor, is affected differently by omega-3 compared 
to omega-6 fatty acids (84). NF-κB influences transcription of 
genes related to cell cycle regulation and inflammatory responses. 
NF-κB is activated not only by arachidonic acid and prostaglan-
din-E2, but also by eicosapentaenoic acid, an omega-3 fatty acid, 
inhibits NF-κB activation (84, 85). We have reported elevated 
NF-κB after short-duration spaceflight, as well as association of 
higher consumption of fish (rich in omega-3 fatty acids) during 
flight with reduced loss of bone mineral density in astronauts 
after long-duration spaceflights (85). Moreover, higher omega-3 
fatty acid intake during bed rest, a spaceflight analog, was associ-
ated with lower excretion of N-telopeptide (a marker for bone 
resorption). The effects of omega-3 fatty acids on inflammatory 
cytokines, specifically TNFα, are well documented on the ground 
(78, 85–87), but further study during spaceflight is warranted.
MiCROBiOMe AND PROBiOTiCS
The symbiotic relationship between humans and their micro-
biome is essential for immune homeostasis (88). Dysbiosis, 
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which often results from an inadequate diet, has been associ-
ated with immune alterations such as increases in inflammatory 
cytokines, T cell imbalances, and autoimmune diseases (88–90). 
A number of studies have investigated how spaceflight affects the 
microbial composition of the astronauts’ gastrointestinal tract 
(GIT). Some of these studies detected compositional changes in 
culturable bacteria collected from the GIT of astronauts spend-
ing up to 2  months in space (91, 92). The identified changes 
included a post-flight reduction of lactobacilli, some of which 
are beneficial to human health (93, 94) and increased levels of 
enterobacteria and clostridia. Another study identified a signifi-
cant pre-flight reduction in bifidobacteria that was attributed 
to the stressful conditions, cosmonauts are exposed to during 
their preparation for the incoming flight (95). It is known that 
several bifidobacteria species secretes antimicrobial peptides 
and confer protection against infections by Gram-negative 
pathogens, such as Salmonella enterica and Vibrio cholera  
(96, 97). It is important to note that most of these studies 
are based on the comparison between the microbial content 
of samples collected pre- and post-flight and only evaluated 
culturable bacteria rather than the genomic profile, therefore, 
extrapolations to what actually happens in space should be done 
with caution.
Due to the rigorous microbiological control implemented 
in spacecraft, the exposure of astronauts to a broad diversity of 
bacteria (including obligate pathogens) is usually very low in 
space. Accordingly, it has been speculated that GIT microbial 
diversity would likely decrease in space. Interestingly, an in-
depth study applying 16S profiling on the intestinal microbiome 
of mice flown for 13 days on the Space Shuttle Atlantis did not 
identify any reduction in the total number of species after their 
return to Earth. Moreover, as previously observed in post-flight 
GIT microbiome samples from astronauts (92), the same study 
reported a higher abundance of clostridiales and fewer lacto-
bacillales (98). Similarly, preliminary in- and post-flight results 
from the Astronauts’ Microbiome project, which investigated the 
impact of the spaceflight and the confined environment on the 
GIT microbiota of crewmembers spending 6 months to 1 year 
onboard the International Space Station, demonstrated that the 
total number of species was not altered, but the abundance of 
species became more even (99).
Whether the observed changes in the GIT microbiota are asso-
ciated with dysregulated immunity or clinical incidence during 
spaceflight has not been determined. However, if a relationship 
is determined, then the implementation of probiotics and other 
alternative treatments, such as prebiotics or nutrient-rich diets 
seem to be a viable spaceflight countermeasure. A spaceflight diet 
rich in nutrients could act as a countermeasure to dysregulation 
of the immune system both directly, as described elsewhere in 
this article, or alternatively by influencing the composition and 
expression of the GIT microbiome. Gastrointestinal microbiota 
metabolize dietary compounds that are indigestible by humans to 
subsequently create accessible metabolites that have been shown 
to modulate immune function (90). More directly, interactions 
between microorganisms in the GIT with immune cells, such as 
Peyer’s patches and dendritic cells, modulate cytokine and T cell 
responses (100).
As noted above, strict microbiological requirements for 
space vehicles reduce important natural exposure to a diverse 
microbiological ecosystem from surface, food, air, and water. The 
introduction of generally recognized as safe probiotic microbes 
to the space food system has potential as a countermeasure to 
immune dysregulation (101, 102). Ground-based evidence from 
human trials indicates that probiotics may reduce symptoms or 
duration of spaceflight relevant conditions, such as skin rashes 
and infections, and respiratory illnesses, and provide immu-
nomodulatory benefits to healthy adults on a strain specific 
basis (102). Probiotic combinations most likely to benefit the 
spaceflight condition are likely to include strains of Lactobacillus 
acidophilus, Lactobacillus casei, and Bifidobacterium bifidum, as 
discussed by Douglas 2017, but specific combinations would have 
to be validated under spaceflight conditions. Studies in intestinal 
cell lines, animals, and humans are beginning to elucidate the 
mechanisms of probiotic interaction with immune cells and 
resulting modulatory responses, which will help guide strain 
selection and improvements (103). Although the impact of pro-
biotics has not yet been determined in spaceflight, initial studies 
in modeled microgravity indicate that strain characteristics may 
transfer to spaceflight (104).
PHARMACOLOgiCAL 
COuNTeRMeASuReS
Host immune responses occur from a flexible and perpetually 
proliferative system composed of multiple lymphoid organs 
(thymus, spleen, lymph nodes, bone marrow, and extensive 
lymphatic vasculature) that collectively weigh about 4 kg spread 
throughout the organism from the brain to the blood and bone, 
from the gut to the liver. Although genomic factors play a pivotal 
role, studies with more than 200 twin dyad subjects have pro-
vided evidence to support the notion that the human immune 
system is fundamentally “shaped” by environmental exposures 
impacted by lifestyle choices (i.e., diet, exercise, social habits, etc.) 
leading to epigenetic changes in gene expression in determining 
specific individual responses to various environmental antigen 
challenges (105).
Classically, clinicians will attempt to assess immune function 
from total and antigen-specific antibody titers, from phenotypes 
of circulating T  cells, and from other lymphocyte subpopula-
tions. Unfortunately, this approach has largely resulted in limited 
clinical applicability for immune-based therapies. The use of cur-
rently available pharmacological countermeasures will likely affect 
both the desired specific immune component (e.g., increasing 
specific antibody titers through enhanced vaccine adjuvants) 
and other immune cell functions (e.g., antigen-specific T  cells 
and nonspecific reticuloendothelial system activation) which can 
impact other organs such as lung and liver and may intensify as 
a function of the duration of exposure. Therefore, proposals to 
test and implement immune directed countermeasures need to 
be embedded into the overall interactions and time slope of space 
altered host immunity.
Before considering pharmacological countermeasures, appropri-
ate operational and environmental conditions must be established. 
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This includes appropriate living conditions, social interactions 
and communication (within the group, with mission control, and 
relatives on Earth), habitat design and privacy, adequate nutrition, 
exercise, sleep, air quality, and circulation. Also, adjustments of 
adequate calorie intake in light of higher body core temperatures 
(106) and avoidance of permanently over-activated sympa-
thetic activities (with concomitant release of stress-permissive 
hormones) need to be considered as an integrated element of 
countermeasure design.
Acute immune-related disease (i.e., allergic respiratory, gas-
trointestinal, cutaneous, and systemic hypersensitivity reactions) 
and acute infections need immediate and targeted chemothera-
peutic measures (e.g., antihistamines, anti-inflammatories, and 
antimicrobials) and symptomatic therapy (fever and pain). The 
“ISS Pharmacy” is designed to provide adequate drugs to treat 
and provide relief for these clinical situations. However, the scope 
of options for pharmacological therapy intended to prevent symp-
toms of immune dysfunction must be carefully chosen. The prime 
and leading decision-making process must follow the principle 
of primum nil nocere. Accordingly, to use a potential pharmaco-
logical intervention, it must be carefully evaluated so the risk of 
causing more harm than good with that particular therapy can be 
minimized or eliminated.
This principle is fundamental for every measure done to 
crewmembers but is especially important for longer lasting 
prophylactic and therapeutic pharmacological treatments. This is 
particularly important for the space program since defining the 
effects (both therapeutic and adverse side effects) expected from 
such drugs in microgravity remain incompletely predictable 
because of insufficient knowledge on drug stability, pharmaco-
dynamics, and kinetics after administration. The multifaceted 
environment associated with space travel may possibly affect 
all of these aspects of drug therapy. These uncertainties add 
further urgency to the need to define the reliability and safety 
of drug use in space especially when planned to be used over a 
longer period of time. Because of the strong interactions and 
integration of the immune system with other organ systems, a 
comprehensive approach must be taken to determine whether 
targeting one challenge to host immunity with a specific phar-
macological intervention may be potentially harmful for another 
physiological system (e.g., adverse effects of anti-inflammatory 
corticosteroids on bone health) which may be enhanced in the 
space environment. Accordingly, a highly integrative approach 
to immune countermeasure development is needed with regard 
to other organ systems. These countermeasures must be—as 
a prerequisite—demonstrated to be safe and effective based 
on experiences on Earth (e.g., in clinical and epidemiologic 
studies).
Sympatho-adrenergic activation in space may have potential 
immune consequences. Compared to Earth, in space systolic arte-
rial pressure and heart rate is typically higher with dysfunction 
of vagal baroreflex control. Sympathetic nerve activity is elevated 
when investigated in astronauts during spaceflight than on Earth 
as microgravity exposure induces a prevalence of sympathetic 
and decreased vagal cardiovascular control (107). NEUROLAB 
experiments provided evidence for an increased sympathetic acti-
vation by showing that norepinephrine (NE) spillover increased 
more than NE reuptake in space. Moreover, the increase of NE 
spillover paralleled the increase of NE in plasma (108) and that 
life in space “triggers long-term neuroplastic changes reflected 
by reciprocal sympathetic and vagal motor neuron responsive-
ness to breathing changes” (109). However, it is still debated 
as to how profound these changes are when compared to each 
terrestrial reference—supine versus upright postural measures 
(110). Key sympathetic transmission and activation hormones 
are the catecholamines epinephrine (E) and NE. Both of these 
hormones are also potent modulators of immune responses 
(111). In vitro studies have demonstrated that epinephrine can 
negatively downregulate LPS-related TNF and IL-1β release in 
healthy subjects and septic patients (112). Epinephrine can also 
alter the normal Th1/Th2 immune balance, which may impact 
likelihood of hypersensitivity reactions (113). Furthermore, 
NE modulates oxidative burst reactions and stimulus-directed 
migration of neutrophils. H2O2 release from granulocytes is sig-
nificantly suppressed by NE in a dose-dependent fashion (111). 
Other conditions of chronic stress exposure (such as those seen in 
astronauts or chronic inflammatory states) confirm this linkage 
between catecholamine release and suppressed polymorphonu-
clear leukocyte function. Significant elevations of plasma E and 
NE levels in astronauts positively correlated with high adaptive 
immune impairments and higher herpes viral shedding (114). 
Recent results further indicate that “autonomic neurons are more 
responsive to epinephrine and corticosterone than are sensory 
neurons, demonstrating that the autonomic nervous system plays 
a substantial role in HSV pathogenesis” (115). Other studies sug-
gest that such catecholamine-mediated stress responses have the 
potential to differentially impact HSV-1 and HSV-2 expression 
and theoretically affect clinical outcomes of an infection. Thus, 
there is a possibility that these individuals could potentially ben-
efit clinically from selected antiadrenergic therapies. Excessive 
sympathetic activity can also suppress antiviral CD4(+) T  cell 
responses and it was also reported in a murine model that anti-
viral CD8(+) T cell responses can be enhanced by administration 
of a β2-adrenergic antagonist (116). Such β-adrenergic antago-
nists can also reduce the capacity for bacterial phagocytosis in 
PMN of post-flight blood samples (117). The significant reduc-
tions in granulocyte oxidative burst capacity and destruction of 
E. coli were observed despite a considerable increase in PMN cell 
count (118).
Beta-blockers, a medication commonly used to affect blood 
pressure, may represent a safe tool to counterbalance space 
flight related sympathetic nervous system activation that could 
lead to adverse immune consequences. Developed by Sir James 
Black in the 1960s many β-blockers now exist, which differ in 
their physicochemical, pharmacokinetic, and pharmacodynam-
ics’ properties. Adrenergic receptors (ARs) exert their function 
via seven transmembrane, G-protein-coupled α- and β-ARs. 
Current β-blocking drugs vary in their selectivity for β1-, β2-, 
and β3-adrenoceptors, and some (e.g., labetalol) are also α1-
adrenoceptor antagonists. The widely used, peripherally and 
centrally acting β-blocker propranolol has similar affinity for 
β1- and β2-adrenoceptors and lower affinity for β3-adrenoceptors 
and is not only used to treat angina and cardiac arrhythmias but 
also as effective therapeutics for hypertension, cardiac failure, 
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glaucoma, migraine, and anxiety. Multiyear experiences have 
reliably identified adverse drug reactions (ADR) associated with 
β-blockers in general. As a group, such ADR include nausea/diar-
rhea, bronchospasm, cold extremities, bradycardia, hypotension 
(e.g., mixed α1/β-antagonist therapy is associated with orthostatic 
hypotension), alopecia (hair loss), hallucinations, vivid dreams, as 
well as with alteration of glucose and lipid metabolism. However, 
a long history of experience with a low overall ADR rate (e.g., 
with two billion defined daily doses, in Germany per year) are 
shown and known to be dose dependent and studies of long-term 
administration of low-dose, selective β-blockers for hypertension 
are in progress even in patients with asthma, a condition that 
normally precludes β-blocker therapy. Recent studies suggest that 
they might also prove useful in diseases as diverse as osteoporosis, 
cancer, or to enhance overall immune performance.
Beta-blockers bind to and block the ARs with no intrinsic 
secondary activation. The expression and function of the target 
ARs have been studied extensively in dendritic cells, lympho-
cytes, and monocytes, and have recently been characterized in 
PMN as well. In murine macrophages, NE and E progress the 
development of a M2 regulatory phenotype in LPS co-culture 
via β-AR signaling, leading to an anti-inflammatory Th2 reac-
tion (119). Since the ROS metabolism in response to different 
stimuli is key to survival, it is worth noting that stimulated 
H2O2 release in granulocytes was significantly inhibited by NE 
in a dose-dependent manner (120) and that β-AR activation by 
NE was the primary mechanism to inhibit the fLMP-induced 
respiratory burst response in  vitro. Gene expression data 
indicates that β1 receptor subtypes might play a pivotal role. In 
addition, this effect was also dose-dependent and was inhibited 
by the application of β-receptor inhibitors in a dose-dependent 
manner. These data suggest a potentially beneficial role for 
β-blockers to enhance innate and adaptive immune responses. 
According to these beneficial immune modulating properties, 
propranolol seems to also affect cancer growth in different 
models and differentially on different organs. Propranolol 
improved recurrence-free survival rates in mice undergoing 
primary tumor excision (121) and has been reported to limit 
the recurrence of melanoma in humans (122, 123). A combina-
tion of cyclooxygenase-2 and β-adrenergic blockade was seen 
to reduce liver metastasis of colon cancer (124) and improves 
metastatic biomarkers in breast cancer patients (125). While 
not all anti-cancer results could be confirmed in large pooled 
analysis, e.g., in breast cancer patients (126), some recommen-
dation was voiced, that a “potential treatment with beta-blockers 
of patients with pancreatic cancer or other malignancies should 
be further evaluated as an adjuvant anti-neoplastic agent in 
clinical trials” (127). Moreover, since action of β2-AR-derived 
signals on NF-κB activity appears to be highly cell type specific 
and gene selective, it will be providing future opportunities for 
the development of selective NF-κB modulators in differential 
immune cell phenotypes (128).
As described in this article, the benefits of exercise and nutri-
tional countermeasures are striking and evidenced to maintain 
bone mass (85, 129). β2-adrenergic activity could further promote 
this protective pattern on bone formation as it inhibits osteoblastic 
activity and in population-based, case-control studies, the current 
use of beta-blockers has been demonstrated to be associated with 
a reduced risk of fractures (130, 131). Also, centrally acting β 
blockers such as propranolol are effective in anxiety disorders, 
though the mechanism of action is not known. Beta-blockers 
are also used for performance enhancement and can be used to 
modulate memory consolidation and retrieval, which prevents 
traumatic memories from forming, conditions which can be 
helpful and necessary in long-duration exploration type space 
missions (132–134).
Endocannabinoids are compounds, endogenously produced 
by enzymes in the cellular membrane, with known anti-inflam-
matory properties including cell cycle regulation in a number of 
leukocyte subsets—similar to ARs—through NF-κB stimulation 
(135). They modulate cell function through a set of cannabinoid 
(CB) receptors, which are primarily expressed in tissue of the 
central and peripheral nervous system (CB1) and on immune 
cells (CB2) (136). Due to the high expression of CB receptors 
in the immune system, endocannabinoids may be a key factor 
in chronic suppression of innate and adaptive immune functions 
(9, 137–139). To date, no reliable data have been reported to pro-
vide an optimal use (timing, duration, and dose) for modulating 
immune cell functions and proliferation in humans. In addition, 
further tests seem unlikely as the first and only approved specific 
CB1 antagonist for use in humans (the medication “Rimonabant” 
in 2007)—was taken off the market due to severe side effects. CB2 
receptor (ant-/partial) agonists (nonspecific and low affinity) are 
available for application in humans and hence an endocannabi-
noid directed countermeasure—although of potential interest 
as a therapeutic target for the prevention and treatment of bone 
diseases—has not yet been pursued.
Stress responses in space and extremely challenging living 
conditions are known to increase the concentrations of free 
cortisol which is proven to have strong immune suppressive 
actions, whether endogenous or iatrogenic. There is substantial 
therapeutic information derived from diseases with pathological 
increase of the production of cortisol by the adrenal glands due to 
a pituitary adenoma (Cushing’s disease) that use pharmacologic 
agents when surgery is not possible. Mifepristone is a com-
petitive glucocorticoid receptor antagonist approved for Cushing 
syndrome and ketoconazole, an antifungal and steroidogenesis 
inhibitor are used in these patients. However, the side effects can 
be considerable (especially for ketoconazole). More recently, new 
drugs have been tested. Hunt and colleagues provided the first 
reliable safety data in a Phase 1 study with CORT125134—an 
orally active, high-affinity, selective antagonist of the glucocor-
ticoid receptor—that is being developed for indications that may 
benefit from the modulation of cortisol activity.
Dose-related safety, tolerability, pharmacokinetics, and phar-
macological effects of CORT125134 were investigated in 81 
subjects and it was demonstrated that CORT125134 prevents 
several effects of the glucocorticoid receptor agonist prednisone 
(140). If such potentially safe and well-titratable drugs seem to 
be an option to limit the effects of a potential and pathologic 
hypercortisolism on Earth, we suggest their evaluation regarding 
immune suppression during spaceflight at least for selected crew-
members. Such studies must, of course, await safety and clinical 
effect immune assessment in ground-based human models.
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BONe COuNTeRMeASuReS  
TO PReSeRve iMMuNiTY
As indicated in the introduction of this review, spaceflight affects 
natural immunity and T-cell responses. Less is known about the 
effects on humoral responses and B cell differentiation. Currently 
available data were obtained using an amphibian species immu-
nized in space, embryos developed in space, or mice subjected to 
HU (HU stands for “hindlimb unloading” a ground-based model 
frequently used to study the effects of spaceflight on rodents). 
These studies revealed that spaceflight can quantitatively and 
qualitatively affect antibody production in response to an anti-
genic stimulation (141–143) and that gravity change can signifi-
cantly reduce B cell activation (144). Furthermore, variations in 
peripheral blood leukocyte subsets have been reported at landing 
both in human and mice (18, 145–147).
Cells involved in natural immunity (e.g., granulocytes and 
monocytes) and immune-competent B and T lymphocytes mature 
from hematopoietic stem cells (HSCs) that are resident in the 
bone marrow in specialized recesses made up of bone and vas-
cular structures, including bone forming osteoblasts and bone 
resorbing osteoclasts (148). Interactions between HSC and these 
bone marrow recesses control the balance between quiescence, 
self-renewal, and differentiation of HSC (149–151). Given 
(i) that prolonged exposure to microgravity induces osteopenia, 
with reduced bone formation and mineralization and elevated 
bone resorption (152–154) and (ii) the required role of HSC–
niche interactions in hematopoietic regulation, changes in bone 
microstructure during spaceflights could lead to changes in the 
function and composition of mature blood cells.
Several reports support this idea. Indeed, a reduction in the 
amount of bone marrow myeloid progenitors, as determined 
by colony-forming assays, was observed both in spaceflight and 
following HU (155–157). In vitro culture of human CD34+ bone 
marrow progenitors during spaceflight confirmed the suppressive 
effect of microgravity on erythropoiesis and myelopoiesis (158) 
and alterations in the maturation/activation of granulocytic cells 
in murine bone marrow were reported after a 13-day spaceflight 
(159). More recently, it was shown that the expression of immu-
noglobulin (Ig) heavy chain and of the lymphoid-determining 
transcription factor Ikaros are modified when amphibian embryos 
are subjected to gravity changes, suggesting a modification in 
B lymphopoiesis (160). This hypothesis was then confirmed in 
HU mice where a decrease in both bone microstructure and B 
lymphopoiesis starting at the stage of early lymphoid-committed 
progenitors was observed (161). T lymphopoiesis is also modified 
under altered gravity conditions as it was shown that exposure 
to hypergravity during gestation affected newborn mice TCRβ 
repertoire diversity (162).
Stress (psychosocial or physical) is another factor to consider 
because it can affect bone microarchitecture (163) and decrease 
the amounts of B and T  cells. Indeed, the administration of 
corticosterone (a stress hormone belonging to the glucocorticoid 
family) to young mice decreased B cell numbers at early stages of 
differentiation (164). Glucocorticoids also increase thymocytes 
apoptosis and affect thymic selections (165, 166). In addition, it 
was recently demonstrated that murine splenic B  cells express 
corticotropin-releasing hormone receptor 2 that affect their 
viability during a stress response (167). Together, these obser-
vations suggest that minimizing stress (using strategies such as 
those presented in the Section “Behavioral Countermeasures”) 
and preserving bone structure could help maintaining astronaut 
immunity.
Several drugs are used to treat osteoporosis. Bisphosphonates 
(Fosamax®, Fosavance®, Adrovance®, Aclasta®, and Actonel®) are 
largely used to preserve bone, but other drugs (e.g., denosumab, 
a human monoclonal antibody that targets RANKL, and the 
ligand of the RANK receptor) exist. Transient changes in the 
numbers of murine HSCs, myeloid-biased progenitor cells, and 
lymphoid-biased cells concurrent with changes to HSC niches 
were reported following zoledronic acid (a bisphosphonate) 
administration (168). Amino bisphosphonates are potent inhibi-
tors of bone resorption and were shown to increase the number 
of granulocytes, indicating that they have an effect on murine 
hematopoiesis (169, 170). As indicated at the end of the Section 
“Nutritional Supplementation/Nutraceuticals,” supplementation 
with omega-3 or polyphenols has a positive impact on bone 
mineral density. These supplementations do also affect hemat-
opoiesis. Indeed, it was shown that a fish oil-rich diet promotes 
hematopoiesis in murine bone marrow and spleen (171) and that 
omega-3 fatty acids impact hematopoietic differentiation (172). In 
the same way, it was reported that curcumin improves anemia and 
extramedullary murine hematopoiesis (173). Another example is 
Amaranthus cruentus extract, rich in polyphenols. This extract 
significantly aided in restoring the levels of red blood cells, white 
blood cells, and hemoglobin in rats treated with phenylhydrazine 
to induce anemia (174). Exercise can also be used as a counter-
measure for disuse-induced bone loss (175) and was shown to 
positively impact antibody production following immunization 
(176). Another promising product is nacre, or mother-of-pearl, 
an acellular calcium carbonate composite produced by mollusks. 
Oral administration of nacre powder has a positive impact on 
murine and human osteoporosis (177, 178) but no studies have 
yet addressed its effects on hematopoiesis. Blood pressure lower-
ing drugs, such as β-blockers, should also be considered as they 
seem to have a positive impact on bone (130, 131).
Together, these examples demonstrate the importance of taking 
into account connections between organs and physiological systems 
in the search for efficient countermeasures, and show that bone 
countermeasures can be considered as a new avenue to protect astro-
nauts from spaceflight-associated immune alterations. Research 
in that direction could also help countering the age-associated 
decline in immune function on Earth. Indeed, alterations of bone 
structure and immune system that manifest under reduced gravity 
conditions have features of accelerated aging. As an example, HU 
rapidly induces modifications presenting many similarities with 
the changes observed in old mice both with regard to trabecular 
bone microarchitecture and to the cellular and molecular changes 
accompanying reduced B cell differentiation (161).
eXeRCiSe
Physical exercise, incorporating both strength and aerobic train-
ing, is regularly performed by ISS crewmembers to counteract 
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reductions in muscle strength, mass, and cardiorespiratory fitness 
that occur due to prolonged periods in the microgravity environ-
ment. An additional benefit of performing exercise in space is it 
has profound effects on the normal functioning of the immune 
system. Indeed, there is a plethora of evidence in the terrestrial 
setting showing that regular exercise of a moderate intensity 
can improve/preserve the normal functioning of the immune 
system (179). For instance, regular exercise has been shown to 
reduce chronic low-grade inflammation by reducing the expres-
sion of toll-like receptors (especially TLR-4) on the surface 
of monocytes, promoting switching of the pro-inflammatory 
M1-type macrophages to the M2 anti-inflammatory type, as well 
as mitigating their downstream inflammatory signaling cascades 
(180). Regular moderate intensity exercise has also been shown 
to improve immune responses to the influenza and pneumococ-
cal vaccines, hasten recovery following experimental rhinovirus 
infection, and reduce self-reported symptoms associated with 
infections of the upper respiratory track (181). Measures of 
immune cell function in vitro are also improved with exercise; 
reductions in LPS-stimulated cytokine release, increases in 
NK-cell cytotoxicity, mitogen/antibody stimulated T-cell prolif-
eration, and neutrophil and monocyte phagocytic and oxidative 
burst activity are often reported to increase following a period 
of structured exercise training (182). Moreover, exercise training 
may also improve mucosal immunity, as the concentration and 
secretion of salivary antimicrobial proteins, such as IgA, LL-37, 
HNP 1–3, lactoferrin, and lysozyme, are elevated in exercise 
trained versus sedentary individuals (183).
The mechanism(s) by which regular exercise alters the plastic-
ity of the immune system are largely unknown but may be a result 
of both direct and indirect effects. The most striking direct effect 
of exercise is the massive and almost instantaneous redistribu-
tion of leukocytes between the blood, lymphoid and peripheral 
tissues that occurs in response to every single exercise bout (179). 
Exercise preferentially mobilizes leukocyte subtypes with effector 
functions (i.e., NK-cells, CD8+ T-cells, CD16+ monocytes, and 
neutrophils) and tissue migration potential, causing a twofold 
to fourfold increase in the total blood leukocyte count almost 
instantaneously (order of minutes). However, this leukocytosis 
is short-lived as there is a rapid extravasation of the mobilized 
leukocytes from the blood to the peripheral tissues and lymphoid 
organs immediately on cessation of exercise (184, 185). Many of 
the leukocytes mobilized with exercise are “primed” and have 
enhanced functional capabilities, including improvements in tis-
sue migration, cytotoxic function, and antigen recognition (184, 
185). This rapid redistribution of immune cells with every exercise 
bout is largely attributable to the effects of catecholamines acting 
on β2-ARs and is believed to enhance immunosurveillance and 
reduce the risk of pathogens from gaining a foothold and causing 
overt disease in regular exercisers. Other hypothesized direct 
effects of exercise include immune cell metabolic reprogram-
ming and increased anti-inflammatory signaling due to regular 
exercise training. Indirect effects of exercise on the immune 
system are largely attributable to changes in body composition 
and metabolism. Reducing fat mass lowers M-1 macrophage 
infiltration to adipose tissue, chronic low-grade inflammation, 
and inflammatory signaling cascades (180). Reductions in the 
cholesterol content of cell membranes that accompany fat loss 
may improve T-cell receptor signaling and MHC translocation 
for antigen presentation, while improvements in cardiovascular 
and endothelial function with exercise may facilitate immune cell 
recirculation between the blood and the lymphoid and peripheral 
tissues (179).
The amount of exercise performed, in terms of both intensity 
and duration, has to be finely balanced to exert the desired posi-
tive effects on immunity. For instance, frequent heavy, prolonged 
bouts of endurance exercise have been associated with immune 
system impairment, latent viral reactivation and increased infec-
tious episodes, which is in stark contrast to the effects reported 
following regular moderate intensity exercise (182). The best 
mode of exercise (i.e., aerobic, strength, or combinations of 
both) for improving/maintaining immune health is subject to 
debate, but the effectiveness of one exercise mode over another 
is likely to depend on the study population and the environment 
by which immunity is challenged or impaired. In a terrestrial 
setting, the evidence is tilted toward aerobic type exercise having 
more profound effects (both positive and negative) on immunity 
than resistance based exercise (182); however, in the spaceflight 
environment, strength training might be more effective due to 
the profound losses in muscle strength and mass, and/or aerobic 
fitness, that occur during flight. Indeed, resistance exercise has 
been shown to increase the release of certain “myokines,” such as 
IL-7, which is essential to maintain thymic function and stimulate 
the release of new T-cells (186). The ideal mode, intensity, and 
duration of exercise performed by astronauts during prolonged 
spaceflight missions will have to be optimized before exercise 
can be used in earnest as an effective countermeasure to offset 
spaceflight-induced changes in immune function.
Fortunately, crewmembers have access to sophisticated exer-
cise equipment on the ISS and are allocated approximately 2.5 h 
daily for exercise. This timeframe includes approximately 1  h 
for strength/resistance training and 30  min for aerobic-based 
exercise training, with the remainder of the time devoted to 
setup/takedown of equipment. For aerobic and cardiovascular 
conditioning, the ISS is currently equipped with a T2 Colbert 
treadmill that comes with elastic straps designed to keep crew-
members in contact with the running belt to generate the foot 
force necessary to elicit an aerobic workout. Crewmembers also 
have access to a recumbent cycle ergometer with vibration isola-
tion and stabilization system, which can elicit resistance in the 
range of 25–350 W. For strength and resistance training, the ISS is 
equipped with the Advanced Resistive Exercise Device (ARED), 
which uses a flywheel and piston-driven vacuum cylinders to 
mimic free-weight exercises at 1G. The resistance levels can be 
adjusted to adequately work all the major muscle groups through 
squats, dead lifts, calf raises, shoulder presses, bench presses, and 
cable/pulley-based exercises. The ARED also comes with an exer-
cise bench assembly, allowing for sit-ups and other core strength 
exercises to be performed. While exercise has been shown to help 
offset spaceflight reductions in muscle strength and mass, it is not 
known if exercise performed on orbit can have protective effects 
on immune system dysregulation.
Terrestrial research in long-term isolation (“MARS-500” 
project) showed that “mild” resistive and cyclic exercises could 
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improve some parameters of adaptive immunity. A significant 
increase of CD4+ T cells subset associated with an elevated pro-
portion of both naive CD4+ T cells (CD4+CD45RA+) and memory 
CD4+ T cells (CD4+CD45RO+) was observed. Concurrently, cyto-
toxic T cells (CD3+CD8+), activated T-helper (CD4+ CD25+bright) 
were not markedly altered from baseline values. The functional 
activity of CD4+ lymphocytes was not reduced during isolation; 
on the contrary, the ability of T cells to be stimulated to express 
the early activation marker CD69 was actually increased. The 
ability of Th1 and Th2 cells to produce cytokines was studied in 
an “in vitro” system. Cytokine production in response to stimula-
tion with the polyclonal mitogen phytohemagglutinin was either 
significantly increased or did not substantially change from the 
baseline values. A noteworthy observation with the cytokine 
profiles at the final period of isolation was a shift in the cytokine 
balance toward Th2 immune response, which is evidenced by a 
reduction in the IFN-γ/IL-10 ratio.
Within parameters associated with humoral immunity, there 
were no significant alterations of Igs IgA, IgM, and IgG or the 
cytokines IL-1α, IL-2, IL-4, IL-6, IL-10, IL12p70, TNFβ, and 
IFN-γ during the physical trainings in the isolation compared to 
the baseline values (187). This data indicate that properly selected 
modes of physical training could be a countermeasure to immune 
dysfunction under stress factors conditions. Alas, very few works 
are devoted to the influence of physical exercises in altered condi-
tions related to the space flight factors on the human immune 
system. Future studies are required to determine the effectiveness 
of exercise as a potential countermeasure to preserve astronaut 
immune health during prolonged spaceflight missions, as having 
a single countermeasure that can simultaneously target several 
physiological systems known to be adversely affected by space 
travel would be particularly advantageous.
vACCiNATiON
Varicella zoster virus (VZV) is a neurotropic alphaherpesviruses 
that causes varicella (chicken pox) on primary infection after 
which it establishes latency in the cranial nerve, dorsal root, auto-
nomic and enteric ganglia along the entire neuraxis. Currently, 
>95% of Americans harbor one or more latent viruses. With a 
decline in VZV-specific cell mediated immunity as seen in the 
elderly, HIV, cancer, transplant recipient, and other immunosup-
pressed individuals, VZV reactivates and typically produces 
zoster (shingles), which can be complicated by chronic pain (pos-
therpetic neuralgia). VZV reactivation can also induce stroke, 
giant cell arteritis, myocardial infarction, cognitive impairment, 
headache, paralysis, vision loss, and other multisystem disorders 
(188). These disorders can occur without the associated zoster 
rash, making diagnosis and appropriate antiviral treatment 
difficult. In such instances, verification of disease produced by 
VZV relies on (i) detection of VZV DNA, anti-VZV IgG or IgM 
antibody in cerebrospinal fluid; (ii) detection of anti-VZV IgM 
antibody in serum, or less often (iii) the presence of VZV DNA in 
blood mononuclear cells. Because VZV DNA is present in saliva 
of patients with acute zoster (189), post herpetic neuralgia (190), 
chickenpox (191), multiple sclerosis (192), and other neurological 
diseases (192, 193), as well as in patients with zoster sine herpete 
(dermatomal distribution pain due to VZV reactivation without 
rash), saliva has been shown to be helpful in diagnosing disease 
produced by VZV in the absence of rash (194).
Since astronaut’s immune system in spaceflight may be 
dysregulated in the setting of microgravity, radiation, prolonged 
stress, or other factors, our laboratory has conducted studies 
on the reactivation patterns of latent viruses, including VZV, 
in astronauts before, during, and after spaceflight. During and 
immediately after spaceflight, VZV DNA was detected in saliva, 
indicative of virus reactivation; no VZV DNA was detected prior 
to spaceflight (195). Furthermore, it was demonstrated that saliva 
contained infectious VZV particles (196). Additional studies 
revealed that 50% of the astronauts shed live, infectious VZV in 
their saliva asymptomatically during short-duration space flight 
(197) and this number increases to 65% in the long-duration 
spaceflights (16). Importantly, a few cases resulted in clinical 
disease manifesting as herpes zoster (195). Taken together, these 
studies indicate that reactivation of VZV, particularly during 
longer duration spaceflights, can potentially lead to clinical 
disease including zoster, chronic neuropathic pain, vision loss, 
and cognitive impairment. Furthermore, continued viral shed-
ding post spaceflight may cause clinical disease in crew contacts 
including uninfected or immunocompromised individuals, as 
well as newborn infants. Thus, it is essential to develop spaceflight 
countermeasures to prevent VZV reactivation and ensure the 
health of the crew, as well as the health of their contacts upon 
return. One such countermeasure is prophylactic administration 
of an antiviral drug against VZV (i.e., valacyclovir). In addition, 
the Flight Medicine Clinic at Johnson Space Center, NASA, has 
initiated vaccination of all crewmembers with Zostavax, a vaccine 
to prevent shingles before spaceflight.
Countermeasures directed at minimizing the impact of viral 
pathogens, such as vaccinations are being evaluated. There are no 
vaccines currently available for any of the eight human herpes 
viruses except for Zostavax that prevents zoster (shingles diseases 
in about 50% of the patients caused by VZV).
BeHAviORAL COuNTeRMeASuReS
As previously noted, there is an established relationship between 
the immune system and psychological stress, circadian rhythms, 
and sleep—key factors that fall within the purview of behavioral 
health management. Since the Shuttle–Mir missions, space agen-
cies have provided psychological support services to crewmem-
bers during their space missions, to help minimize stress and 
promote well-being and performance. This support may include 
individual monitoring of cognitive function and psychological 
health, facilitating connections with family, and fatigue manage-
ment services.
For ISS crewmembers, private psychological conference (PPC) 
between the astronaut and a psychologist or psychiatrist, once 
every 2 weeks, provides the opportunity for the crew to discuss 
issues related to mission stressors (if any). These PPCs may be 
conducted through real-time video conferencing, and last between 
15 and 20 min. As noted by Beven (198), topics discussed can 
include sleep, fatigue, crew relationships, mood and cognition, 
family relationships, and habitability issues.
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For US crewmembers, a psychologist also evaluates neurocog-
nitive function via monthly WinSCAT (Space Flight Cognitive 
Assessment Tool for Windows) assessments. This neurobehav-
ioral battery is intended to not be sensitive to daily stressors 
such as fatigue, and instead serves as a brief test to assess more 
severe changes in cognition, such as those that could result from 
a significant event (e.g., head injury, exposure to a toxin). A crew-
member’s score on the WinSCAT in-flight is evaluated relative 
to their individual baseline performance prior to mission. The 
WinSCAT is also administered post-mission to ensure cognitive 
function is comparable to pre-mission performance.
In addition to in-flight monitoring, international space agen-
cies facilitate regular crew communication with their families 
during their mission. Services such as private video conferences, 
an updateable family webpage, and personalized crew care 
packages delivered to the ISS, help offset prolonged separation 
from home. Such evaluation and support may even begin before 
crewmember selection, and behavioral professionals will assess 
applicants and their ability to manage family issues and cope with 
prolonged family separations, as well as their ability to perform 
under extreme conditions. For NASA, while behavioral scientists 
do not participate in final selection decisions, their recommenda-
tions are considered, and may lead to a crew which inherently 
manages stress more effectively.
Additional pre and in-mission services include the area of 
fatigue management. Objective and subjective evidence from 
spaceflight missions shows that circadian rhythms are misaligned 
and astronaut sleep is reduced on orbit (199–201) even with 
regular use of hypnotics (200). Prior to flight, crews also must 
endure intense training schedules and frequent transmeridian 
travel which results in circadian misalignment and sleep loss 
leading up to a mission. As a result, NASA behavioral scientists, 
in partnership with flight medical operations, offer services specific 
to fatigue management prior to flight and in mission. Crew are 
offered training courses, one-on-one assessments to review their 
specific sleep history, and they are given protocols for ground 
testing hypnotic and alertness medications so that in-flight pre-
scriptions may be titrated appropriately. A recent focus in fatigue 
management has been on the use of light and dark as a coun-
termeasure for maintaining circadian alignment, both in flight 
and prior to flight. Hence, crews are given recommendations for 
schedule shifting (as in cases of jet lag) and for maintaining a 
nominal sleep-wake schedule.
These support services are intended to offset the pre-flight 
stress of training, transmeridian travel, high workload prior to 
flight, as well as in-flight stressors such as circadian misalign-
ment, prolonged isolation, confinement, and separation from 
home. Agency focus on mitigating stress and optimizing crew 
health likely benefits the immune function of the crew, based 
on the established terrestrial literature which demonstrates that 
minimizing stress, sleep loss, and circadian misalignment is 
related to improved immune function (202, 203).
Missions of exploration may be very different from orbital 
flight, from the perspective of behavioral and stress management. 
Many of the countermeasures offered today for orbital flight are 
facilitated by LEO and the specific attributes or capabilities of 
ISS. Current mitigations such as the delivery of personalized 
crew care packages, and private crew quarters for conducting 
PPCs, will be unavailable, or at minimum limited in scope. In 
addition, planned Mars missions (both flyby and planetary sur-
face operations) will introduce communication delays between 
the crew and mission control, and the crew and their families at 
home, which will impact this support negatively. Given the direct 
relationship between psychological health and immune function, 
international behavioral scientists should work to ensure the level 
of behavioral and stress management on ISS may be extended to 
deep exploration missions, within operational constraints.
DiSCuSSiON
To venture far from our planetary home, before immersing 
ourselves in new risks (the space exposome), we must first work 
to ensure the safety of our voyagers. We now know we have an 
“immune problem,” which may elevate certain clinical risks, 
and which could likely be solved with appropriate biomedical 
countermeasures. A discussion of countermeasures must care-
fully consider the precise nature of the in-flight dysregulation. It 
is now understood that immune balance alteration is common 
during flight: diminished T/NK cell functions, increased inflam-
matory plasma cytokine levels for the duration of a 6-month 
orbital spaceflight. Concurrently, there is persistent reactivation 
of latent herpesviruses, a putative biomarker for diminished 
cell-mediated immunity (19). Also, some ISS crewmembers 
manifest some degree of clinical incidence, primarily infectious 
events, allergic symptoms, or skin rashes (22). It is debatable if 
these incidence numbers are “elevated,” considering the unique 
nature of humans who serve on an ISS mission: extremely 
physically and psychologically fit individuals who are medically 
screened and undergo a pre-flight quarantine, living in a quasi-
isolation chamber. Characterization of this complicated in-flight 
phenomenon is ongoing, via several NASA, European, Japanese, 
and Russian flight (or ground analog) investigations. However, 
enough is known about the status of the immune system, as it 
equilibrates during long-duration orbital flight (“space normal”) 
to begin consideration of potential countermeasures. In fact, 
given the limited lifespan of ISS, and the anticipated start date for 
missions beyond the Van Allen belt, it is indeed appropriate to 
now consider immune countermeasures for spaceflight such that 
countermeasures could be validated either in ground analog or 
onboard ISS within its lifespan.
It is important to distinguish operational mitigations, direct or 
indirect countermeasures, and treatments. Operational mitiga-
tions are items that block physiological dysregulation prior to 
occurrence. The current screening of crew, vehicles, and payloads 
are a successful mitigation of infectious disease, however, they 
do not rectify any physiological dysregulation, nor do they com-
pletely eliminate infectious disease risk. A true countermeasure 
will attempt to normalize, as much as is possible under the 
assault of stressors during deep space missions, the physiological 
dysregulation of the immune system. Such immune “boosters” 
will include nutritional supplements, functional foods, and other 
organic compounds, and are the majority of the countermeas-
ures considered in this review. Medications may be divided 
into both countermeasures and treatments. Any medication 
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countermeasures (i.e., beta-blockers) considered must be safe 
enough for long-term use, and would have a positive effect on 
immune balance, mitigating the factors which cause immune 
dysregulation. Medical treatments (i.e., antivirals, antibiotics, and 
antiallergics) are not used to rectify immune dysregulation, but to 
treat a specific occurrence of an adverse medical event. Therefore, 
while relevant for exploration, medical treatments do not fix the 
underlying physiological dysregulation, which may have been the 
initiator of the adverse medical event.
The emerging approaches of precision medicine might be 
enabling as we consider the concept of individualized immune 
countermeasures. For example, we know that some crewmembers 
experience persistent hypersensitivity reactions during space-
flight. In some cases, these events are serious enough to require 
treatment with topical or oral steroids and while usually managed 
do not completely resolve during flight. Atypical allergy symptoms 
(mostly respiratory and cutaneous), occur in crewmembers who 
describe themselves as “non allergic” on Earth, are commonly 
reported and often result in crewmembers who subsequently 
take antihistamines for the duration of their mission (21). Other 
crewmembers report absolutely no immunologic-related adverse 
clinical events during spaceflight.
A greater understanding of the genomic backgrounds of the 
crewmembers as well as their terrestrial responses (transcrip-
tomic, proteomic, cytokines, as well as antibody repertoires) to 
immune perturbations (such viral infection) may provide impor-
tant insights as to how to individualize countermeasures in flight. 
Crewmembers’ molecular responses with prior experiences to 
stress, prolonged terrestrial isolation, or even previous short- 
or long-duration spaceflight would be extremely informative. 
Undoubtedly, there is individual susceptibility to adverse events 
following spaceflight exposures; therefore, rather than a validated 
suite of countermeasures which apply to all crewmembers, it may 
be that countermeasures must be tailored to our knowledge of 
the individuals known immune response to these exposures. This 
knowledge may guide precision strategies to avoid their down-
stream consequences of disease and promote greater astronaut 
health in prolonged missions.
When considering an operational immune countermeasure 
for deep space exploration missions, we suggest that such con-
sideration cannot be discipline-specific. Spaceflight is not a single 
variable, but a collection of stressors that adversely affect multiple 
human systems. As previously discussed, the immune system is 
a sentinel system, extremely interrelated with all of the body’s 
other systems (Figure 1). Therefore, any countermeasures imple-
mented to benefit immune function may affect other systems, and 
conversely any countermeasures implemented to benefit other 
systems (bone, cardio, etc.) will very likely affect the immune 
system. We would not necessarily assume such a cross-discipline 
effect would always be beneficial. For these reasons, ground (in 
appropriate terrestrial analog) and flight validation of spaceflight 
countermeasures is essential.
When ground-based validation of countermeasures is con-
ducted, experimental design should consider altered circadian 
rhythms. T cell subpopulations can show pronounced circadian 
alterations, regulated via altered release of cortisol and cat-
echolamines, as well as activation of the major stress hormones 
during daytime. These cellular sensitivities favor immediate 
effector defense but can diminish longer-term adaptive immune 
responses, which could then be affected by AR antagonism 
(204). Moreover, endogenous catecholamines affect thymocyte 
apoptosis/proliferation, which are also dependent on age and 
thymic activity (205). Elevations in core body temperature 
during spaceflight were recorded recently (106), which may 
affect sympatho-adrenal activation (e.g., with β-blockers) and 
therefore indirectly influence various immune networks. For 
pharmacological intervention, it is imperative to determine an 
optimal dose and therapeutic period. In addition, it is of equal 
importance to define a strategy for pharmacologic withdrawal to 
reduce/prevent clinical sequelae upon return to Earth, such as 
orthostatic intolerance.
In this product, we will refrain from proposing a “specific” 
recipe for a spaceflight immune countermeasure. This is because 
the in-flight nature of the dysregulation is still being defined by 
multiple international investigations. For example, Tregs represent 
a major determinant of immunity, particular anti-inflammatory 
influence, and the successful resolution of an immune response, 
however, there is a dearth of human evidence in the literature 
about their behavior in the microgravity environment. Treg 
immunology is an intense field of inquiry. In addition to char-
acterizing Treg responses in mice and human subjects, current 
efforts aim to define the means to control Treg function. Many of 
the countermeasures proposed in this review have been described 
to influence Treg number, frequency, and some function—for 
example, intense exercise (206, 207), diet/probiotics (208), and 
pharmaceuticals (beta-blockers) (209). The problem is that, so 
far, there is no report of a method to target Tregs specifically; all of 
the interventions have perturbed the entire T cell compartment; 
some subpopulations more than others. Since Tregs represent 
a “brake” on the immune system, their role in the microgravity 
environment is curious; elevated Treg frequency and function 
should inhibit allergic responses—which appear in crewmem-
bers in-flight at a higher than normal incidence rate—however, 
they may exacerbate the T  cell lethargy that is a hallmark of 
the clinical immunosuppression crewmembers suffer during 
their missions. While there is a pressing need for data defining 
the human Treg response in the microgravity environment, we 
should not consider Tregs as a central player in countermeasure 
strategies. Rather, Treg characterizations must be included in 
the overall T  cell analytical portfolio; understanding how to 
modulate the equilibrium between effector/inflammatory and 
regulatory responses in space will be essential for an operative 
immunologic countermeasure. Several ongoing or upcoming 
spaceflight immunologic studies have incorporated Treg profiles 
in their analyses, so novel insight into these—as well as other 
important, under-investigated immune subsets—should be 
forthcoming. Since the first generation of countermeasures at our 
disposal offer a broad scope of influence, a comprehensive survey 
of the immune system—evaluating both innate and adaptive cell 
subsets simultaneously—will be necessary to assess, predict, and 
validate the efficiency of any immunologic countermeasure.
Furthermore, immunological countermeasures for space-
flight will likely require personalization. Any “screening test” to 
evaluate crews requiring any augmented countermeasures (for 
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example, any crew predisposition to persistent dermatitis) must 
also be defined. It is likely that for deep space flyers, a pre-mission 
“immunological screen” will be beneficial for selecting personal-
ized countermeasures. Such testing might include a thorough 
medical history including allergy and hypersensitivity incidence, 
a basic immune/inflammation assessment, and seropositivity 
for various latent viruses; perhaps patch testing for items crews 
commonly contact onboard, such as wipes. Also, exploration 
mission specifics such as the nature of the exploration vehicles, 
mission design, planned nutrition, and available exercise equip-
ment all are yet to be defined. However, as we have now identified 
a myriad of logical options, we may certainly outline the most 
likely basic components of the eventual deployment immune 
countermeasure.
First, we will assume all multisystem human factors have been 
optimized. These include exercise equipment and daily regimen, 
radiation shielding, and psychological support via communica-
tion with family and friends on Earth. Current research efforts 
by international behavioral scientists should seek to understand 
the impact of these exploration-specific stressors to the well-
being and cognitive function of the crew, and to ensure proper 
behavioral and stress mitigations are in place so that the current 
level of care (on ISS) is implemented as closely as possible (within 
operational constraints) for future missions of deep space opera-
tions. All of these measures are likely to benefit immune health, 
but may not be able to completely eliminate the cellular dys-
regulation. Second, diet and nutrition will have been specifically 
optimized for exploration missions. This includes establishment 
of nutrient content and stability, inclusion of functional foods 
with bioactive molecules, as well as tailoring the diet to meet daily 
requirements. Third, if necessary the diet will be supplemented 
with some combinations of antioxidants, probiotics, omega-3/
anti-inflammatory, or other compounds which will benefit 
immune physiology. Any specific supplementation combination 
would require validation in a terrestrial analog (likely Antarctica 
winterover), and hopefully during orbital spaceflight on ISS, prior 
to exploration deployment.
Finally, a long-term pharmacotherapy may be considered, 
such as beta-blockers or new glucocorticoid antagonists. Great 
care will be required when considering months to years dura-
tion of pharmacological treatment, however, such measures may 
be required for the unique condition of deep space missions. 
Combining countermeasures—exercise, food, and pharmaco-
therapy—seems like a good compromise and testing β-blocker 
propranolol at a dose of 20–40  mg as an integrated, immune 
countermeasure. This because of the relatively solid evidence 
that it is well titratable, positively affecting—beyond the immune 
system—other key organ systems as well and combining dif-
ferential countermeasures multiply the benefits as seen for other 
organs (85). However, its testing in Earth-bound and then space 
missions need to consider age-related and gender effects and will 
eventually lead to a more holistic and efficient and effective coun-
termeasure concept for long-duration spaceflight. To confirm 
this suggested therapeutic avenue, the relationship between the 
pharmacological effectiveness of beta-blockers and the patho-
genesis of osteoporosis, immune dysfunction, cardiovascular 
and cognitive (dys-)function must be explored in standardized, 
space-like conditions on Earth. Currently, interspace agency and 
polar institute research projects in the coastal and high Antarctic 
plateaus are conducted to investigate such effects in a systematic 
manner, and reflecting space-mission-relevant a conditions and 
exposition times (210) and may be expanded to test for combined 
pharmacological countermeasure applications in the future. Also, 
recognize that countermeasures validation requires a laboratory 
determination their efficiency during space flight even if they were 
tested intending the participation of certain astronaut. As men-
tioned above, the immune system is one of the most complicated 
regulatory systems in the human body and plays an important 
role in many physiological processes. Any changes to test regime 
conditions of internal factors such as neuro-endocrine status, 
shifts in gut microflora balance, psychological stress, etc., differ-
ent combination and strength of external factors (microgravity, 
radiation, temperature, pressure, etc.) could lead to a situation 
in which the immune system would respond differently and the 
suggested countermeasure would not be as productive as it was 
considered. In this situation, the chosen countermeasure system 
should be rapidly changed. That is why it is very necessary in 
parallel with countermeasures to develop new laboratory equip-
ment for the orbital and deep space missions.
In summary, it now appears after decades of “distance,” that 
exploration space missions are within sight. New heavy lift rockets 
are in development, as are capsule vehicles capable of sustaining 
humans during deep space missions beyond the Van Allen belt. 
NASA and ESA, in conjunction with other international space 
agency partners, are moving forward with plans for a lunar pres-
ence, via a cis-Lunar station, surface operations, or both. Mars 
flyby missions, without the complications of entry descent and 
landing, should follow the lunar missions, with the eventual long-
term goal of landing humans on the surface of Mars. Eventually, 
as spaceflight becomes routine, it should become open not only 
to most healthy adults but also to children and individuals with 
physiological disabilities. We still suffer from a lack of complete 
understanding regarding how the immune system of healthy 
adults functions in spaceflight conditions. We do know we should 
perform research to find out how the space-associated extreme 
factors can influence the immune system of people with aller-
gies, atherosclerosis, autoimmune diseases, immunodeficiencies, 
endocrine pathology, etc. to find strict contraindications for space 
missions and to test all described above countermeasures. The 
near term plans appear realistic, and the international community 
of immunologists should work to complete our understanding 
of spaceflight immune dysregulation, and move forward to the 
validation of appropriate countermeasures.
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